Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
BMJ Case Rep ; 20162016 Jul 21.
Article in English | MEDLINE | ID: mdl-27444140

ABSTRACT

Vaginal cancer is a rare malignancy accounting for 1-2% of all pelvic neoplasms. Dissemination usually occurs through local invasion and rarely metastasises to distal locations. Metastasis of vaginal cancer to the breast is extremely infrequent and unique. A 66-year-old Asian woman presented with vaginal bleeding and was found to have a vaginal mass and a left breast mass. Pathological assessment of the biopsies revealed identical squamous cell characteristics of both masses. We describe a very rare and novel case of a distally located vaginal carcinoma with metastasis to the breast Federation of Gynecology and Obstetrics (FIGO) stage IV (FIGO IVB). Robot-assisted extrafascial total hysterectomy with local vaginal mass excision and partial mastectomy of the left breast were performed. After surgery, the patient underwent adjuvant chemotherapy followed by breast and pelvic radiotherapy, with maintained complete remission after 3 years of follow-up. This combination of findings and treatment is very distinct with a unique and favourable response.


Subject(s)
Breast Neoplasms/secondary , Vaginal Neoplasms/pathology , Aged , Biopsy , Breast/pathology , Breast Neoplasms/therapy , Female , Follow-Up Studies , Humans , Treatment Outcome , Vaginal Neoplasms/therapy
2.
Arch Gynecol Obstet ; 273(2): 119-21, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16091940

ABSTRACT

INTRODUCTION: Acute fatty liver (AFL) of pregnancy is a difficult and challenging diagnosis. The treatment plan is usually supportive. CASE REPORT: We present a case of a patient with AFL of pregnancy and Gram-negative endomyometritis and sepsis. Our treatment plan included the use of activated protein C (APC). CONCLUSION: This is the first case report of the use of APC in a post-partum patient with AFL and sepsis.


Subject(s)
Anticoagulants/therapeutic use , Fatty Liver/drug therapy , Pregnancy Complications/drug therapy , Protein C/therapeutic use , Acute Disease , Adult , Female , Humans , Pregnancy , Puerperal Disorders/drug therapy , Sepsis/drug therapy
3.
Am J Obstet Gynecol ; 189(6): 1563-7; discussion 1567-8, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14710065

ABSTRACT

OBJECTIVE: The purpose of this study was to assess the complication rates of incidental appendectomies in women who undergo benign gynecologic procedures. STUDY DESIGN: This was a retrospective case-controlled study of patients who did (n=100 women) or did not (n=100 women) undergo incidental appendectomies at the time of an abdominal hysterectomy between June 1995 and January 2001. Information was abstracted from hospital and clinic records and a gynecologic oncology database. Data were obtained about age, body mass index, hypertension, diabetes mellitus, the number of days with nothing by mouth, the length of hospital stay, and postoperative complications (cellulitis, fever, ileus, pneumonia, thromboembolic disease). Data were analyzed with the use of two-sample t tests, Wilcoxon Rank sum tests, chi(2) tests, and multiple logistic regressions. RESULTS: There was no difference in preoperative diagnosis or operative procedure for either group. The number of patients in the group that did have incidental appendectomy versus the group that did not have incidental appendectomy with additional procedures at the time of abdominal hysterectomy was bilateral salpingo-oophorectomy (66 vs 61 women), unilateral oophorectomy (19 vs 19 women), lysis of adhesions (9 vs 8 women), and others (12 vs 8 women). Compared with the group that did not have incidental appendectomy, the group that did have incidental appendectomy was younger (mean age+/-SD: 44+/-9.6 years vs 48+/-13.6 years, P=.02) and had a lower mean body mass index (26.1+/-6.0 kg/m(2) vs 29.8+/-8.9 kg/m(2), P=.0009). No significant differences were found between the two groups (the group that did have incidental appendectomy vs the group that did not have incidental appendectomy, respectively) with respect to the following postoperative complications: fever (40 vs 27 women), cellulitis (1 vs 2 women), wound collection (4 vs 6 women), wound dehiscence (1 vs 5 women), wound abscess (7 vs 6 women), ileus (3 vs 2 women), and urinary tract infection (4 vs 10 women). The mean length of hospital stay was significantly longer in the group that did have incidental appendectomy than in the group that did not have incidental appendectomy (3.6+/-1.52 days vs 3.1+/-1.1 days, P=.006). However, the difference was no longer significant when patients who were fed electively on the postoperative day 2 were excluded from the analysis (3.16+/-1.13 days vs 3.04+/-1.13 days, P=.507). Thirty-one percent of the histologic specimens were abnormal, with fibrous obliteration being most common, and there was one case of acute appendicitis. CONCLUSION: An incidental appendectomy at the time of benign gynecologic procedures does not increase postoperative complication rates or length of hospital stay. The inclusion of incidental appendectomies in all abdominal hysterectomies could potentially decrease the morbidity and mortality rates because of appendicitis in elderly women.


Subject(s)
Appendectomy/statistics & numerical data , Hysterectomy/statistics & numerical data , Medical Errors , Postoperative Complications/epidemiology , Adult , Appendectomy/adverse effects , Appendectomy/methods , Case-Control Studies , Female , Follow-Up Studies , Humans , Hysterectomy/methods , Incidence , Incidental Findings , Length of Stay , Logistic Models , Middle Aged , Probability , Reference Values , Retrospective Studies , Risk Assessment , Statistics, Nonparametric
4.
Curr Opin Oncol ; 14(5): 519-27, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12192271

ABSTRACT

In this era of advanced medical technology, recurrent ovarian cancer continues to be a therapeutic dilemma. Most of these patients will succumb to their disease process. For this reason, it is of paramount importance for all clinicians to recognize that the primary goal of salvage therapy is to maximize disease-free survival and quality of life. With this goal in mind, they can offer patients a variety of different modalities to control disease, including second-look surgery, secondary or interval cytoreduction, second-line chemotherapy, hormonal therapy, and immunotherapy. The role of second-look surgery has yet to be delineated, but the modality can be helpful in evaluating disease status and guiding further therapy in patients receiving first-line platinum-based chemotherapy or in research protocols. Interval cytoreductive surgery has been shown to confer a survival advantage in a small subset of patients with localized resectable disease proven to be platinum sensitive. The choice of chemotherapeutic agents and the prognosis depend directly on whether the patient is a platinum-sensitive responder. Many agents are approved for the treatment of recurrent ovarian cancer, and the treatment of each patient should be individualized depending on the cumulative toxicities and performance status. Extensive ongoing research trials are underway to elucidate the best salvage therapy.


Subject(s)
Evidence-Based Medicine , Neoplasm Recurrence, Local , Ovarian Neoplasms/therapy , Salvage Therapy , Second-Look Surgery , Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/pharmacology , Clinical Trials as Topic , Cytokines/therapeutic use , Decision Making , Female , Humans , Immunotherapy , Laparotomy , Prognosis , Quality of Life
SELECTION OF CITATIONS
SEARCH DETAIL
...